Advanced Biomed Inc.

ADVB

Nasdaq; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0001941029


None

No letter

4 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $13.8M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, late filer, thin data not computable: short runway, distress, fortress balance sheet
Inputs computable	4 of 14
Graded from	filings received through Oct 13, 2026 20 days before the rescan; latest periodic filing 10-K received Oct 13, 2026
Last close	$2.83 2026-10-29; market equity $4.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Oct 8, 2025

in the State of Nevada. We operate through Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan is responsible for the main operation and the design and development of the company's primary technologies and products. Since our establishment in 2014, we have been focusing on the integration of multiple interdisciplinary technologies and established our own microfluidic technology platform. Utilizing the physical and molecular biological characteristics of tumor cells, we have developed various advanced and original research through the joint application of semiconductor technology and biotechnology.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 97.8						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	47.1%	(6.6%)	97.8	803	2026-06-30
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 14.6					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	8.58	(0.35)	11.1	748	2026-06-30
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	9.33x	2.92x	18.1	829	2026-06-30
Growth and financing, sleeve percentile 76.3					
Revenue growth, three-year compound	not computable	10.1%			
four annual observations are required; found 1					
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 1					
Reinvestment rate	not computable	37.1%			
required facts have no common fiscal period end					
Asset growth, three years	not computable	2.2%			
four annual observations are required; found 2					
Net share issuance, one year	52.7%	2.5%	76.3	631	2026-10-13

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 52.7%
Late filer	found 3 NT 10-K/Q filings in the last eight quarters
Thin data	4 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-10-29 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(35.2%)	(2.2%)	27
Distance from 52-week high	(87.9%)	(28.7%)	5
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(154.1%)	(1.0%)	5
Book value to price	3.23	0.28	98
Sales to price	0.03	0.30	12
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.60)	(0.19)	27

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-06-30	
Return on assets above zero	pass
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	fail
Long-term leverage fell	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	20 (10-K received Oct 13, 2026)
Median daily dollar volume, 63 sessions	$249,444

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	$6.7M	2026-06-30	2026-10-13	10-K	26-109029
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$1.9M	2026-06-30	2026-10-13	10-K	26-109029
3	assets	us-gaap:Assets	$13.8M	2026-06-30	2026-10-13	10-K	26-109029
4	assets	us-gaap:Assets	$22.9M	2025-06-30	2026-10-13	10-K	26-109029
5	current assets	us-gaap:AssetsCurrent	$13.7M	2026-06-30	2026-10-13	10-K	26-109029
6	current liabilities	us-gaap:LiabilitiesCurrent	$1.5M	2026-06-30	2026-10-13	10-K	26-109029
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$12.6M	2026-06-30	2026-10-13	10-K	26-109029
8	operating income	us-gaap:OperatingIncomeLoss	-$6.2M	2026-06-30	2026-10-13	10-K	26-109029
9	book equity	us-gaap:StockholdersEquity	$12.3M	2026-06-30	2026-10-13	10-K	26-109029
10	liabilities	us-gaap:Liabilities	$1.5M	2026-06-30	2026-10-13	10-K	26-109029
11	revenue	us-gaap:Revenues	$127,637	2026-06-30	2026-10-13	10-K	26-109029
12	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,652,133	2026-10-13	2026-10-13	10-K	26-109029
13	shares outstanding	dei:EntityCommonStockSharesOutstanding	21,640,000	2025-10-08	2025-10-08	10-K	25-097465

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.